Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2008

bioMérieux Boosts Molecular Diagnostic Portfolio with Purchase of AviaraDx for $60M

  • bioMérieux acquired AviaraDx for $60 million expanding its portfolio of infectious disease molecular diagnostics to include tests that aid cancer management. The firm also gains AviaraDx’ CLIA-certified lab.

    AviaraDx will operate as an independent legal entity called bioTheranostics. The company has traditionally been focused on R&D with 19 employees and a limited sales team. bioMérieux reports that AviaraDx has had restricted sales and is projected to lose approximately $8 million this year. bioTheranostics is also predicted to have lower sales until 2012 and break even around that year.

    AviaraDx’ diagnostic tests are used to classify cancers on a molecular level to assist with prognosis. The company also has reportedly validated cancer biomarkers and capabilities in gene-expression profiling in tissues.

    Aviara CancerTYPE ID® provides cancer classification, especially for patients diagnosed with metastatic cancer where the origin is uncertain or unknown. Aviara Breast Cancer Index is used to evaluate two Aviara markers (H/I and MGI) for risk prognosis and treatment-response prediction for chemo and hormonal therapy.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »